7/31/2013

Samsung BioLogics signed a 10-year deal to manufacture Bristol-Myers Squibb's melanoma drug Yervoy, or ipilimumab, at its facility in Songdo Incheon, South Korea. Samsung is beginning trial production, and commercial production will follow the securing of regulatory OKs.

Full Story:
PharmaTimes (U.K.)

Related Summaries